Most of us are familiar with the different classes of eye drops.
Eye drops are typically initially released in a branded patented version by a single company. Eye care’s prior three most successful branded patented eye drops, which all reached $1 billion or more in annual sales, were Timoptic (timolol maleate ophthalmic solution) from Merck and Co., Xalatan (latanoprost ophthalmic solution) from Pfizer, now Viatris, and Restasis (cyclosporine ophthalmic emulsion 0.05%) from Allergan, now AbbVie. While on patent, these eye drops first sold for $300 to $500 per bottle. Once a new drug’s